Thomas A. Davis
11Patents
6h-index
23Co-inventors
66Inventor score
Filing activity: Oct 28, 1993 → Nov 16, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7452535B2 | Methods of treatment using CTLA-4 antibodies | Human Necessities | 46 | Expired |
| US5599703A | In vitro amplification/expansion of CD34.sup.+ stem and progenitor cells | Chemistry; Metallurgy | 44 | Expired |
| US6642049B1 | Human brain endothelial cells and growth medium and method for expansion of primitive CD34+CD38-bone marrow stem cells | Chemistry; Metallurgy | 22 | Expired |
| US8142778B2 | Methods of treatment using CTLA-4 antibodies | Human Necessities | 19 | Active |
| US8510245B2 | Bayesian clinical decision model for determining probability of transplant glomerulopathy | Physics | 7 | Active |
| US6572867B1 | Inhibition of xenoreactive antibodies | Human Necessities | 6 | Expired |
| US10668152B2 | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment | Chemistry; Metallurgy | 1 | Active |
| US10392442B2 | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment | Chemistry; Metallurgy | 1 | Active |
| US10726943B2 | Clinical decision model | Physics | 1 | Active |
| US11965031B2 | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment | Chemistry; Metallurgy | 0 | Active |
| US9457052B2 | Allograft tolerance induction | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.